共 179 条
[1]
Doukky R(2013)Impact of appropriate use on the prognostic value of single-photon emission computed tomography myocardial perfusion imaging Circulation 128 1634-1643
[2]
Hayes K(2013)The prognostic value of cardiac SPECT performed at the primary care physician’s office J Nucl Cardiol 20 519-528
[3]
Frogge N(2012)Attenuation of the side effect profile of regadenoson: A randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. “The ASSUAGE trial” J Nucl Cardiol 19 448-457
[4]
Balakrishnan G(2013)Attenuation of the side effect profile of regadenoson: A randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease-the ASSUAGE-CKD trial Int J Cardiovasc Imaging 29 1029-1037
[5]
Dontaraju VS(2013)The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation J Nucl Cardiol 20 205-213
[6]
Rangel MO(2014)Regadenoson use in patients with chronic obstructive pulmonary disease: The state of current knowledge Int J Chron Obstruct Pulmon Dis. 9 129-137
[7]
Doukky R(2018)Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review J Nucl Cardiol 25 137-149
[8]
Frogge N(2012)Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching JACC Cardiovasc Imaging 5 1014-1021
[9]
Balakrishnan G(2015)Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging J Nucl Cardiol 22 600-607
[10]
Hayes K(2020)5-year prognostic value of quantitative versus visual MPI in subtle perfusion defects: Results From REFINE SPECT JACC Cardiovasc Imaging 13 774-785